16 December 2025
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.
FutureTech II Acquisition Corp.
CIK: 1889450•2 Annual Reports•Latest: 2025-04-09
10-K / April 9, 2025
Revenue:N/A
Income:-$746,953
10-K / April 5, 2024
Revenue:N/A
Income:$2,911,502
10-K / April 9, 2025
Company Summary
Business Overview
- Company Name: FutureTech II Acquisition Corp.
- Type: Blank check company (Special Purpose Acquisition Company - SPAC)
- Formation Date: August 19, 2021
- Purpose: To effect a merger, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target businesses.
- Industry Focus:
- Disruptive technology sectors, specifically:
- Artificial Intelligence (AI)
- Robotics
- Biomedical life sciences
- Target geographic region: U.S.
- Not pursuing initial business combinations with entities primarily in China (including Hong Kong and Macau)
- Disruptive technology sectors, specifically:
- Target Characteristics:
- Companies with positive cash flow or compelling technology with a clear path to profitability.
- Companies with large market potential, especially in hardware tech, biomedical sciences, AI, and Robotics.
- Businesses with proprietary or patented technology, significant market position, or distinct competitive advantages.
- Companies at inflection points that could benefit from operational improvements.
Management and Strategy
- Management Lead: Ray Chen, CEO and Chairman
- Experience in tech, media, and investment sectors, including prior roles as CFO and COO of other SPACs.
- Key Strategy:
- Source, acquire, and manage technology-focused businesses.
- Drive operational improvements and growth organically or through acquisitions.
- Leverage relationships with deal sources to maintain a strong pipeline of potential targets.
- Use a criteria-based evaluation process, with flexibility to pursue targets outside initial guidelines.
Financials and Operations
- Initial Public Offering (IPO):
- Date: February 18, 2022
- Units offered: 11,500,000 units at $10.00 each
- Gross proceeds: $115,000,000
- Private Placement:
- 520,075 units purchased by the Sponsor at $10.00 each
- Total gross proceeds: $5,200,750
- Trust Fund:
- Approximately $117.3 million (from IPO and private placement) deposited in trust for public shareholders' benefit.
- Offices: Located at 128 Gail Drive, New Rochelle, NY
- Employees:
- Currently, only one officer, who devotes varying amounts of time to the company's affairs.
- Revenue and Income:
- The company has not engaged in any business operations or generated revenue or income. Its purpose is to identify and complete a business combination.
Business Development
- Current Status:
- Engaged in searching for a target; no business operations or revenue yet.
- Filed a Form S-4 regarding a merger with Longevity Biomedical, Inc., expected to be completed, subject to approvals.
- Upcoming Milestones:
- Deadline to complete business combination: August 18, 2025 (extensions possible).
- Pending a potential business combination with Longevity Biomedical that would involve a merger and a name change.
Additional Notes
- The company has not disclosed any number of customers, specific revenue, or profit since it is still in the pre-operation phase, solely focused on identifying and completing a merger with a target entity.
- The company’s strategy includes targeting innovative tech firms with high growth potential in AI, robotics, and biomedical sciences within the U.S. market.
